ArticlePloS one2009
Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.Journal of proteomics · 2013Trial
- Let-7c-3p Suppresses Ovarian Cancer Progression by Targeting S100A6 and Inhibiting JAK-STAT Signaling.Cancers · 2026Article
- Increased cytoplasmic and nuclear S100A6 expression is associated with improved prognosis in ovarian cancer.BMC cancer · 2026Article
- Exploring human plasma proteomic variations in mucolipidosis type IV.Molecular therapy. Methods & clinical development · 2025Article
- Advances in S100 protein family for gynecological malignancies.Discover oncology · 2025Review
- Article
- Calcium signals and potential therapy targets in ovarian cancer (Review).International journal of oncology · 2023Review
- S100A6: molecular function and biomarker role.Biomarker research · 2023Review
- The Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential.Biomolecules · 2023Review
- An Integrated Approach to Protein Discovery and Detection From Complex Biofluids.Molecular & cellular proteomics : MCP · 2023Article
- Proteomic Profiling of Fallopian Tube-Derived Extracellular Vesicles Using a Microfluidic Tissue-on-Chip System.Bioengineering (Basel, Switzerland) · 2023Article
- S100A6 Protein-Expression and Function in Norm and Pathology.International journal of molecular sciences · 2023Review
- Article
- Article
- Comprehensive analysis of the expression and prognosis for S100 in human ovarian cancer: A STROBE study.Medicine · 2020Article
- Identification of diagnostic upper gastrointestinal cancer tissue type-specific urinary biomarkers.Biomedical reports · 2019Article
- Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells.Communications biology · 2019Article
- Prognostic values of S100 family members in ovarian cancer patients.BMC cancer · 2018Article
- S100A6 protein: functional roles.Cellular and molecular life sciences : CMLS · 2017Review
- Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.Gynecologic oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundOvarian cancer is the 5th leading cause of cancer related deaths in women. Five-year survival rates for early stage disease are greater than 94%, however most women are diagnosed in advanced stage with 5 year survival less than 28%. Improved means for early detection and reliable patient monitoring are needed to increase survival. METHODOLOGY AND PRINCIPAL
findingsApplying mass spectrometry-based proteomics, we sought to elucidate an unanswered biomarker research question regarding ability to determine tumor burden detectable by an ovarian cancer biomarker protein emanating directly from the tumor cells. Since aggressive serous epithelial ovarian cancers account for most mortality, a xenograft model using human SKOV-3 serous ovarian cancer cells was established to model progression to disseminated carcinomatosis. Using a method for low molecular weight protein enrichment, followed by liquid chromatography and mass spectrometry analysis, a human-specific peptide sequence of S100A6 was identified in sera from mice with advanced-stage experimental ovarian carcinoma. S100A6 expression was documented in cancer xenografts as well as from ovarian cancer patient tissues. Longitudinal study revealed that serum S100A6 concentration is directly related to tumor burden predictions from an inverse regression calibration analysis of data obtained from a detergent-supplemented antigen capture immunoassay and whole-animal bioluminescent optical imaging. The result from the animal model was confirmed in human clinical material as S100A6 was found to be significantly elevated in the sera from women with advanced stage ovarian cancer compared to those with early stage disease.
conclusionsS100A6 is expressed in ovarian and other cancer tissues, but has not been documented previously in ovarian cancer disease sera. S100A6 is found in serum in concentrations that correlate with experimental tumor burden and with clinical disease stage. The data signify that S100A6 may prove useful in detecting and/or monitoring ovarian cancer, when used in concert with other biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.